Latigo Biotherapeutics (LTGO) Stock Price, News & Analysis

Company Overview

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid medicines for the treatment of acute and chronic pain. The company focuses on selectively targeting Nav1.8, a sodium channel involved in the transmission of pain signals, with the goal of developing therapies that may provide pain relief without the risks associated with opioid medications.

Latigo’s pipeline includes small-molecule Nav1.8 inhibitors, led by LTG-001 for acute pain and additional research programs aimed at chronic pain conditions. The company is focused on advancing these candidates through clinical development and has not established a commercial product portfolio.

Latigo was founded in 2021 with backing from life-sciences investors, including Third Rock Ventures. Its activities have been centered on research and clinical development in the United States. As a development-stage biotechnology company, its future operations depend on the results of clinical trials and regulatory review of its investigational therapies.

Key Stats

• Today's Range: $17.00 to $18.26
• 50-Day Range: N/A
• 52-Week Range: $17.00 to $25.93
• Volume: 274,588 shs
• Average Volume: 314,291 shs
• Market Capitalization: $1.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $52.25
• Consensus Rating: Buy

Latigo Biotherapeutics Stock Analysis - MarketRank™

Latigo Biotherapeutics scored higher than 94% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Latigo Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Latigo Biotherapeutics has a consensus price target of $52.25, representing about 204.7% upside from its current price of $17.15.

Amount of Analyst Coverage

Latigo Biotherapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.68% of the float of Latigo Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Latigo Biotherapeutics has a short interest ratio ("days to cover") of 2.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Latigo Biotherapeutics has recently increased by 45.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Latigo Biotherapeutics does not currently pay a dividend.

Dividend Growth

Latigo Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.42

News Sentiment

Latigo Biotherapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Latigo Biotherapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for LTGO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Latigo Biotherapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $5,040,000.00 in company stock, which represents 0.4433% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Latigo Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,040,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

Latigo Biotherapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/03/2026
• Today: 9/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:LTGO
• CIK: 2056611
• Web: latigobio.com
• Phone: 805-716-2927
• Fax: N/A
• Employees: 59
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Latigo Biotherapeutics: $52.25
• High Price Target: $73.00
• Low Price Target: $36.00
• Potential Upside/Downside: +204.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 66,300,000
• Free Float: N/A
• Market Cap: $1.14 billion
• Optionable: N/A
• Beta: N/A